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a b s t r a c t 
Biomaterials for regeneration of the intervertebral disc must meet complex requirements conforming to 
biological, mechanical and clinical demands. Currently no consensus on their characterization exists. It 
is crucial to identify parameters and their method of characterization for accurate assessment of their 
potential efficacy, keeping in mind the translation towards clinical application. This review systemati- 
cally analyses the characterization techniques of biomaterial systems that have been used for nucleus 
pulposus (NP) restoration and regeneration. Substantial differences in the approach towards assessment 
became evident, hindering comparisons between different materials with respect to their suitability for 
NP restoration and regeneration. We have analysed the current approaches and identified parameters 
necessary for adequate biomaterial characterization, with the clinical goal of functional restoration and 
biological regeneration of the NP in mind. Further, we provide guidelines and goals for their measure- 
ment. 
Statement of significance 
Biomaterials intended for restoration of regeneration of the nucleus pulposus within the intervertebral 
disc must meet biological, biomechanical and clinical demands. Many materials have been investigated, 
but a lack of consensus on which parameters to evaluate leads to difficulties in comparing materials as 
well as mostly partial characterization of the materials in question. A gap between current methodology 
and clinically relevant and meaningful characterization is prevalent. In this article, we identify necessary 
methods and their implementation for complete biomaterial characterization in the context of clinical 
applicability. This will allow for a more unified approach to NP-biomaterials research within the field as 
a whole and enable comparative analysis of novel materials yet to be developed. 
© 2020 Acta Materialia Inc. Published by Elsevier Ltd. 
This is an open access article under the CC BY license. ( http://creativecommons.org/licenses/by/4.0/ ) 
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Low back pain affects millions of people worldwide, leading to
 high economic burden. Often, this pain originates in the inter-
ertebral disc (IVD) of the spine due to disc degeneration [1 , 2] .
VDs allow for stability and flexibility of the spine in multiple
egrees-of-freedom while providing resistance to axial compres-
ion and a centre of rotation in the functional spine of vertebrates.rticle under the CC BY license. ( http://creativecommons.org/licenses/by/4.0/ ) 
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Fig. 1. Potential biomaterial features influence treatment goals after tissue degeneration within the NP. 
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O  Within the IVD, the ligamentous annulus fibrosus (AF) confines the
gel-like nucleus pulposus (NP) in the centre, while the cartilagi-
nous endplates (CEP) connect the IVD to the adjacent vertebrae on
the cranial and caudal surfaces. The NP is an isotropic, fibre rein-
forced, gelatinous, water-rich and swollen core providing compres-
sive resistance as well as a centre of rotation for movement [3–7] .
Prior to adolescence, large vacuolated notochordal cells (NCs) can
be found in the human NP, which maintain the NP [8 , 9] and mostly
disappear with adolescence, being replaced by small nucleus pul-
posus cells [10 , 11] diminishing the regenerative capacity of the
IVD. Disc degeneration slowly sets in, often culminating in neck
and low back pain in adults many years later during the normal
ageing processes, or at an accelerated rate in some individuals [12] .
Degeneration of the IVD is a complex and multifactorial:
genetic, molecular, cellular and mechanical process all lead to
an imbalance between production and degradation of the ECM,
initially within the NP [13 , 14] . Increased catabolic processes de-
crease the content of glycosaminoglycans (GAGs) and therefore
the swelling capacity of the NP. The pressure within the IVD
drops and thus leads to altered mechanical loading of the disc
as a whole, tissue injury, vascularization and neoinnervation with
infiltration of immune cells can then occur [4 , 15–20] . Additionally,
calcification of the CEP inhibits nutrients from entering the IVD as
well as waste removal [21 , 22] . With build-up of waste products
like lactic acid, the pH decreases [23] , which reduces cell viability
and accelerates disease progression [24] . The painful symptoms
of degenerative disc disease (DDD) are largely an end result of
the altered extracellular matrix composition: altered mechanical
loading [25] , invasion of nociceptive nerves and production of
neurotropic agents [20 , 26–29] and/or painful mechanical loading
of adjacent structures due to reduced disc height or herniation [7] .
Currently, few treatment options are clinically available for
DDD. These focus on pain management, removal of extruded
disc tissue, and IVD replacement as a whole or spinal fusion
[3 , 30] . Commercially available IVD or NP replacement materials
are often made from metal [31 , 32] or non-degradable polymer
blends [33 , 34] . These restore motion segment mobility but do not
regenerate the tissue, while exhibiting a broad range of potential
adverse effects (possible degradation of neighbouring vertebrae
[35] , restricted range of motion [36] , and more [37] ). Therefore,
it is critical to develop new strategies that promote IVD regen-
eration, have a viable translation to the clinic and improve the
quality of life of the patient. As early IVD degeneration occurs
mostly in the nucleus, the NP represents a promising target when
considering potential therapies. Therefore, tissue engineering withP bio-instructive materials presents an alternative to current
reatments. Biologically compatible materials to restore the dam-
ged tissue will not only be useful to restore NP functionally by
estoring disc height, but also as a delivery vehicle for cells and/or
iomolecules for re-establishing a healthy tissue. This distinction
etween NP restoration and regeneration also imposes different
ey requirements on the biomaterials in question ( Fig. 1 ). 
Although several clinical trials have already explored injectable
iomaterials for NP restoration [38] , it is crucial to accurately
ssess biomaterials for their efficacy in vitro and ex vivo prior
o clinical trials. However, comparing between various bioma-
erials for NP restoration is hindered by differing biomaterial-
haracterization approaches. ISO 10,993–1 provides standards for
valuating biocompatibility of medical devices and ISO18192–2 in-
ludes recommendations for mechanical testing for spinal nucleus
rostheses. These provide an overview and the legal framework
ut need modifications when testing e.g. biologically derived
iomaterials for tissue regeneration. [39] For further standards
hat can serve as templates we refer to ASTM-E111–17 (Young’s
odulus), ASTM-F2346–18 (Artificial Discs), ASTM-F2423–11 (Total
isc Prostheses), ASTM-D2990–17 (Mechanical Testing of Plastics),
STM-F2789–10 (Mechanical and Functional Characterization of
ucleus Devices) and ISO 10,993–9 (Biological Evaluation of Medi-
al Devices). Identifying key principles in research for biomaterials
s necessary for a patient-orientated advancement, understanding
f clinical treatment of degenerated NP and reducing the number
f potentially failed in vivo and in-patient studies. 
Here, we discuss necessary considerations and evaluation pa-
ameters for potential biomaterials from conceptual design to in
ivo study. We provide resources for more information and high-
ight new approaches to known challenges. Finally, we suggest
uidelines for the mechanical, biological and in vivo characteriza-
ion of biomaterials for IVD regeneration. 
. Methods 
PubMed and Web of Science were searched for publications
n NP restoration materials using the following keywords in
he abstract or title: ((Intervertebral disc OR nucleus pulposus
R intradiscal) OR (injectable AND disc) OR disc OR (injectable
ND nucleus pulposus) OR nucleus pulposus regeneration OR
ucleus pulposus repair OR nucleus pulposus replacement OR
ucleus pulposus substitute OR nucleus pulposus tissue engineer-
ng OR nucleus pulposus tissue regeneration) AND (biomaterial
R hydrogel OR scaffold NOT annulus NOT anulus NOT spinal
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Table 1 
Matrix composition of human nucleus pulposus tissue. Adapted from Antoniou et al . (2004). 
Thompson grade of 
lumbar NP tissue 
H 2 O (%) [55] GAG (μg/mg dry 
weight) [55] 
Collagen (μg/mg 
dry weight) [55] 
Elastin:Collagen 
ratio [45] 
Protein (μg/mg dry 
weight) [55] 
1 -/- -/- -/- 0.08 ± 0.02 -/- 
2 82.7 ± 4.2 622 ± 152 18 ± 9 286 ± 67 
3 78.7 ± 4.5 384 ± 207 29 ± 15 0.28 ± 0.05 434 ± 196 
4 76.3 ± 5.0 230 ± 204 27 ± 9 596 ± 248 
5 75.0 ± 1.4 86 ± 42 24 ± 1 501 ± 174 
Table 2 
Human NP mechanical properties are affected by degeneration state of the tissue. Adapted from Johannessen et al . (2005), Yang 
et al . (1998) and Iatridis et al . (1997). All measurements were taken at ambient temperature. 
IVD Thompson Swelling pressure Effective aggregate Bulk modulus Magnitude of complex modulus 
grade (MPa) [47] modulus (MPa) [47] (MPa) [56] (kPa) at 1 rad/s, 10% strain [46] 
1 0.139 ± 0.029 1.01 ± 0.43 1720 ≈5 ± 4 
2 
0.037 ± 0.038 0.44 ± 0.19 
≈17 ± 10ol 
3 -/- 
4 ≈22 ± 10 
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Table 3 
Pressures recorded intradiscally in vivo in human subjects during various 
routine postures and exercises (adapted from Wilke et al . (1999)). 
Posture Pressure (MPa) 
Lying 0.10 – 0.12 
Standing 0.5 
Sitting (no backrest) 0.46 – 0.55 
Walking 0.53 – 0.65 
Lifting 20 kg (rounded back) 2.3 
Lifting 20 kg (straight back) 1.7 
≈  
l  
[
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r  usion NOT lumbar fusion NOT cage NOT whole disc). Publications
eaturing computational, cell-only, whole-disc, spinal fusion, an-
ulus fibrosus-only approaches and from conference proceedings
ere further excluded. Ten further papers were additionally found
uring publication review. Thus, 270 publications in total were
dentified, and their methodology analysed for this review. 
. Results 
.1. The human np biomechanical environment 
In the NP, notochord-derived NP cells (NPCs) are found [40 , 41]
n low numbers ( ≈4 × 10 3 cells/mm 3 ) [42] , and the extracellu-
ar matrix (ECM) is composed mostly of water-attracting GAGs. A
allmark is a high GAG:hydroxyproline ratio around 27:1 and a
ollagen-II:collagen-I ratio of roughly 6:1 in healthy NPs [43 , 44] ,
hile degeneration is associated with increase in elastin:collagen
atio ( Table 1 ) [45] . The decrease in GAGs in the NP during de-
eneration leads to lowered swelling pressure of the disc and
onsequently lower aggregate and instantaneous shear modulus
 Table 2 ) [46 , 47] . Within the normal disc, osmolarities of 450–550
Osm have been reported, in addition to an oxygen concentration
f ≈2.6–13% in vivo and a pH of ≈7 in discs with no visible patho-
ogical changes. [23 , 48] The range of motion in a healthy lumbar
pine has been reported to be ca. 50 ° in flexion, 20 ° in extension
nd ca. 30 ° in right or left lateral flexion [49 , 50] . In the lumbar
pine 9 ° of axial rotation were observed [51] . Pressures in the spine
re posture dependant, and have been quantified by Wilke et al .
1999) [52] ( Table 3 ). Strains within the human IVD range betweenTable 4 
Purposes and characteristics of biomaterials used for nucleus pulposus restor
DOF: degrees of freedom, ECM: extracellular matrix. 
Purpose 
Mechanical - Anatomical restoration (IVD height) 
- Biomechanical restoration (flexibility in multipl
Biological - Inhibition of degenerative processes 
- Inhibition of catabolic factors and cytokines 
- Prevention of nerve and blood vessel ingrowth 
- Stimulation of regeneration 
Clinical - Pain relief 
- Minimally invasive 
- Does not migrate/extrude 
- Economically and translationally viable? 7% (non-degenerate disc) to ≈11% (degenerate disc) [53] . Natural
oading frequencies were reported at about 4–5 Hz (25–35 rad/s)
54] . 
.2. Current approaches to biomaterial characterization 
Most biomaterials developed for IVD regeneration have been
ested in vitro (~60%) for their cytotoxicity and effect on gene
xpression in 3D cell cultures, whereas only 30% actually con-
ucted in vivo studies, implanting the biomaterial in question
nto quadrupeds ( Fig. 3 ). Biomaterials for NP restoration should
deally address both, mechanical and biological, aspects of IVD
estoration/regeneration, while also considering the applicability
nd translation into a clinical setting from the beginning ( Table 4 ).
onsequently, a broad range of parameters must be considered
uring development and related to their effect on the material ef-
cacy and their performance over time within the disc ( Fig. 5 ). A
ange of different materials have been investigated ( Fig. 2 ). Whileation and regeneration. IVD: intervertebral disc, NP: nucleus pulposus, 
Characteristics 
e DOF) 
- Swelling properties similar to NP 
- Material & mechanical characteristics similar to NP 
- Reservoir for cells, proteins and/or growth factors 
- Allow tissue remodelling 
- Non-immunogenic 
- Integration into NP ECM 
4 T.C. Schmitz, E. Salzer and J.F. Crispim et al. / Acta Biomaterialia 114 (2020) 1–15 
Crosslinker Types
Biomaterials
Fig. 2. Biomaterials used in ≥5% of studies (top) and crosslinking methods (bottom) considered for nucleus pulposus restoration. ECM = extracellular matrix, pNI- 
PAM = Poly(N-isopropylacrylamide), PEG = polyethylene glycol, PLGA = poly(lactic-co-glycolic acid), PGA = poly(glycolic acid), PLA = poly(lactic acid, UV = ultraviolet light). 
In 
Vit
ro
Ex
 Vi
vo
In 
Viv
o
Fig. 3. Experiment types conducted in studies published. In vivo refers to 
any application of the biomaterial in question within an animal (subcuta- 
neous/intradiscal/intramuscular implantation). Total number of preclinical studies: 
270. 
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t  ifferent materials require different characterization methods,
ertain parameters are critical to understand the suitability for
n vivo applications ( Table 6 ). Similarly, identifying an appropri-
te target patient population influences therapeutic strategy, mate-
ial development and characterization. While injectable materials
n their own may be applicable to symptomatic early to moder-
te disc degeneration or prophylactically used in segments adja-
ent to total disc replacement or fusion, they could also be used
ost-herniation where a combined NP and AF approach or whole
VD would be needed. In such situations preformed materials re-
lacing the whole IVD may reduce the risk of re-herniation com-
ared to injected materials without annulus repair [57] . 
To bridge the gap between mechanical and biological require-
ents of biomaterials, mostly naturally-derived hydrogels have
een explored ( Fig. 2 ). Many ECM-components can be used as
hey can form networks with immense swelling capacity, but dis-
dvantages are their weak mechanical properties, difficult pro-
essability and risk of disease transmission. Synthetic biomateri-
ls allow tailoring of their biomechanical properties, and are easy
o manufacture and process. Both classes can be degradable or
T.C. Schmitz, E. Salzer and J.F. Crispim et al. / Acta Biomaterialia 114 (2020) 1–15 5 
Fig. 4. Parameters investigated in nucleus pulposus restoration and regeneration studies. AFM = atomic force microscopy, DMA = dynamic mechanical analysis, ECM = ex- 
tracellular matrix, MRI = magnetic resonance imaging, SEM = scanning electron microscopy, TEM = transmission electron microscopy, AFM = atomic force microscopy. 
Synthec Hydrogel
Tissue-derived 
hydrogel
Producon/Processing Characterizaon Assessment
• Base material 
(monomer)
• Crosslinking agent
• Decellularizaon
remnants       
• Crosslinking agent
Sterilizaon
• EtO
• Irradiaon
• Autoclavaon
• CO2
• Biocompability
• (Bio)degradaon
• Infiltraon and 
remodeling by cells
• Cell phenotype In Vitro
• Disc height restoraon
• Injectability & Extrusion
• Biomechanics Ex Vivo
• Disc height restoraon
• Biocompability
• Biodegradaon
• Inflammaon
• Infiltraon and 
remodeling by host cells
• Cell phenotype In Vivo
• Swelling
• Porosity
• Injectability
• Mechanical behavior
Biological Parameters
Material Parameters
Fig. 5. Parameters of biomaterial systems that need to be evaluated for nucleus pulposus restoration & regeneration. 
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t  on-degradable: non-degradable polymers allow the fabrication of
aterials with higher mechanical performance however they can
ack biological cues, potentially affecting cell infiltration and tis-
ue integration and can illicit immune responses [58 , 59] . On the
ther hand, some non-degradable biomaterials have been devel-
ped which enable cellular migration, are biocompatible and do
ot illicit an immune response [38 , 60 , 61] . Degradable biomaterials
an be remodelled by the cells and the growing tissue, however
he degradation rate must meet the tissue reformation rate. 
To date, research groups mostly consider the immediate ben-
ficial biological effects at the cell and tissue level exerted by the
iomaterial, i.e. cell viability, gene expression and ECM deposition
 Fig. 4 ). In contrast to this, inflammatory markers, cell senescence
nd apoptosis are seldom considered. Subcutaneous implantation
n small animal models is often performed but does not provide
nformation about the suitability of the material in its clinical
etting of the degenerated IVD. AF or CEP rupture can lead tonflux of inflammatory cells, which is especially pertinent to
CM-derived materials, or cell-delivery approaches. Investigations
nto the functional restoration of the NP in vivo are performed
n quadrupeds and therefore examination of the biomechanical
erformance of the material is only partly transferable to the
onditions found in the human spine [62–65] . Similarly, applying a
iomaterial intradiscally warrants an inspection of damage done to
he AF, and maintenance of the intradiscal pressure. Other aspects
uch as biomaterial compatibility with GMP standard sterilization
ethods are often neglected. 
From a mechanical point of view, mostly unconfined compres-
ion tests and rheology are performed to understand the bioma-
erial’s behaviour under physiologically relevant stresses. While
welling behaviour is also often considered, the porosity is sel-
om investigated, although this parameter influences the swelling
ehaviour and interaction of cells with the material. Degrada-
ion of the biomaterial over time is only examined in some stud-
6 T.C. Schmitz, E. Salzer and J.F. Crispim et al. / Acta Biomaterialia 114 (2020) 1–15 
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mies. Injectability for later application to the patient, particularly in
biomaterials serving also as cell-carriers, is neglected, and rather
approximated by rheological data. 
Due to the lack of methodological consensus, much partial
biomechanical data on various materials has been published,
which still might profit from further experiments. In the follow-
ing sections we discuss material evaluation parameters, resources
for in-depth analyses of material choice and testing, as well as
appropriate techniques to answer research questions. 
3.3. Sterilization methods and their potential effect on biomaterials 
Every biomaterial intended for use in a clinical setting must be
sterilized according to GMP practices without rendering its me-
chanical properties and bioactivity unsuitable for its intended pur-
pose. Assessing the success of sterilization usually is done by con-
firming a reduction in microbial load by a factor of 10 6 and details
on organisms to be used have been published by the FDA [66 , 67] .
Additionally, various testing methods for bacterial endotoxins
have been established in the past years which is interesting espe-
cially for materials of animal origin due to potential septicaemia.
[68] Current FDA-approved sterilization methods include dry heat,
autoclaving, ethylene oxide (EO), and gamma-irradiation [67] . Sev-
eral studies demonstrated that biomaterial properties change using
these techniques: ethylene oxide was shown to influence mechan-
ical properties as well as ultrastructure of decellularized porcine
bladder matrix [69] , while γ -irradiation of human dermis leads
to protein denaturation and degradation [70] . Similarly, synthetic
materials may be affected by γ -radiation (initiating additional
crosslinking or unspecific scission) [71] . Dry heat/autoclaving often
exceeds the polymers’ melting point [71] in addition to denaturing
proteins [72] . Residual levels of chemical sterilants like ethylene
oxide on the biomaterial could also impair cell viability and/or
phenotype. They therefore need to be quantified and completely
removed prior to utilization in cell culture or patients [73 , 74] .
Peracetic acid has been often discussed as a less harmful sterilant
compared to the FDA-recognized ones, with a required immersion
into liquid peracetic acid that allows for complete (exterior &
interior) sterilization. As NP replacement strategies rely in part on
the material’s swelling, immersion-based approaches seem coun-
terproductive prior to material application into the disc. Further,
while peracetic acid is commonly referred to as less damaging, it
seems to impair tissue remodelling post-implantation [75] . 
One novel approach for sterilization utilizes supercritical CO 2 
to eliminate microbial contamination within the sample while
retaining biomaterial properties [74 , 76–78] and thus could repre-
sent a gentle processing method for biomaterials which require it.
Future research efforts thus need to identify suitable sterilization
methods for NP replacement materials. Alternatively, aseptic pro-
duction might provide a route to sterile biomaterial production for
materials sensitive to the aforementioned sterilization techniques,
albeit with significantly higher costs. 
3.4. Characterization of mechanical and material properties 
Ideally, biomaterials need to restore the disc’s height and
biomechanical properties mimicking the NP’s material properties
and withstanding physiological loading conditions. As such, mea-Table 5 
Test regimen for compression/shear testing recommended by the FDA and ASTM. ROM =
Test Samples Cycles 
Static and dynamic compression testing All ≥6 10,000,000 
Compression shear testing 
Static and dynamic compression testing Until failure uring the swelling capacity is needed to judge the necessary vol-
me of material for intradiscal application. This can be easily mea-
ured by immersing the biomaterial into PBS at 37 °C and weigh-
ng it at predetermined timepoints covering at least a 30 day pe-
iod or longer, depending on the material [79] . Important here is
djusting the buffer to an osmolarity mimicking that of the (de-
enerated) disc [80] . The porosity of the material not only influ-
nces the water and nutrient uptake, but also potential infiltration
f NP cells or migration of co-administered cells [81] . Pore-sizes
f 150–300 μm have been recommended for fibrocartilaginous tis-
ues [82] , and scaffolds with this pore size have been success-
ully employed in vitro for NP tissue engineering [83 , 84] . Impor-
antly, SEM sample preparation should not affect the pore size, and
nap-freezing samples in liquid nitrogen is an advised preparation
ethod [85] . The degree of crystallinity of a polymeric hydrogel
lso determines many of its mechanical and biological properties
ike stiffness and biodegradability and should therefore be evalu-
ted via e.g. differential scanning calorimetry [79 , 86–88] . 
Complementing this information with data from uniaxial con-
ned compression testing (mimicking its placement in the IVD)
ill result in a detailed understanding of the biomaterial’s re-
ponse to mechanical deformations and stresses. The FDA guidance
ocument 1637 and ASTM standard F2423–11 provide guidelines
or conducting axial compression tests on total disc prosthesis
hich also pertain to NP replacement strategies ( Table 5 ). Addi-
ionally, the sample should be tested in a bovine serum solution of
0 g/l protein content at 37 °C. Experiments should be run for 10
illion cycles on > 6 samples to establish validity of the material.
trains and loading rates should reflect or exceed physiological
alues (see above). Dynamic and diurnal loading with loads,
trains and frequencies that best mimic the in vivo situation are
ecommended (e.g. based on ASTM F2789 & F2423–11). Fatigue
ests should be run in load and displacement control for 10 million
ycles on > 6 samples to establish validity and safety of the ma-
erial. 10 million cycles reflect approx. 80 years of activities, and
hus, a material withstanding such a number of cycles is currently
onsidered to be safe for long-lasting use. 
An ex vivo approach can be used to investigate the suitability
f the material under study. In the context of mechanical test-
ng, many parameters might influence the performance of the ma-
erial apart from the material’s properties themselves, including
.g. material storage and preconditioning [89–91] . Using cadaveric
nimal/human motion segments allows for cyclic compression as
ell as torsional testing. Ideally, a setup providing six degrees of
reedom provides insights into the resulting range of motion and
ts restoration to the previously stated values [89] . Additionally,
he Poisson’s ratio informs about material’s expansion and subse-
uent the load distribution from NP to the AF, and can be obtained
rom unconfined compression experiments or digital image corre-
ation [92 , 93] . Further, rheological measurement inform about the
aterial’s response to shear, strain and temperature, which again
hould resemble or exceed physiological values (see Section 3.1 ).
emperature measurements should cover a range of at least 20 °C
 37 °C but may be extended in either direction in case of thermo-
esponsive materials. 
A powerful mechanical testing method is unconfined and con-
ned dynamic mechanical analysis, where many of the described
easurements can be obtained [94] .  Range of motion. 
Frequency (Hz) ROM 
All 1 – 2 -/- 
Max. allowed for by machine, > physiological ROM 
-/- 
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a  .5. Assessing cytocompatibility and bioactivity in vitro 
Preliminary assessment of the material in vitro can already pro-
ide insight into the applicability of the biomaterial in vivo . Effects
f production/processing, subsequent sterilization and degradation
nto cells can easily be observed employing a cell viability assay.
dditionally, cell infiltration into the biomaterial, cell phenotype,
nd deposition of ECM by the cultured cells are of major interest. 
Residual presence of antigens, pathogens and pyrogens for
issue-derived decellularized scaffolds must be assessed to pre-
ent hyperacute rejection, long-term chronic inflammation after
mplantation and disease transmission. Most studies focus on
emaining cellular debris [95] and DNA (due to transmittance
f e.g. endogenous viruses [96 , 97] ) using chemical or enzymatic
olutions [74] . Currently, few studies examine the removal of
he Gal α1–3-gal β1-(3)4GlcNAc-R epitope ( α-Gal) ( Fig. 4 ) [98 , 99] ,
lthough humans naturally express antibodies against α-Gal [100] .
t plays a diverse role in host response to the biomaterial, rang-
ng from hyperacute graft rejection in humans [98 , 100–102] to
aster remodelling due to macrophage infiltration into the tissue
103 , 104] . Elucidating its effect in NP regeneration is therefore
ritical. The α-Gal specific M86 antibody has been successfully
sed in immunohistochemical detection and quantitative enzyme-
inked immunosorbent assays (ELISAs) have been developed with
his antibody [105–108] . Complement activation studies should
lso be considered, as not only the total amount of α-Gal, but also
he density of the antigen within the tissue plays a role in eliciting
n immune response [109] . 
Controlling biomaterial degradation rates particularly in a de-
enerate disc with elevated matrix degrading enzymes may be
roblematic [110] . Degradation products must not be harmful for
he surrounding environment or compromise the healing process.
requently used synthetic polymers for IVD regeneration are made
rom poly(lactic-co-glycolic acid) or poly(glycolic acid) [84 , 111] . De-
pite suitable mechanical properties, their degradation leads to the
elease of acidic monomers into the diseased IVD [112] . This po-
entially lowers the pH in the disc beyond its already low value,
nhancing the degradation processes. Masking this decrease in pH
equires addition of basic compounds into the biomaterial (e.g.
odium bicarbonate) [113] , the effect of which on IVD tissue is
ot known. In contrast to this, hydrogels employing e.g. polyethy-
ene glycol (PEG) compromise cellular remodelling within the NP
fter implantation as PEG degrades very slowly under the condi-
ions found in the IVD [59] and contains no natural binding sites
or cells. A similar situation is true for agarose and alginate, as both
annot be degraded enzymatically in mammals [114–116] . 
In vitro degradation studies are often carried out in PBS over
arying time periods, often adding enzymes to the buffer to
ore accurately reflect in vivo conditions [117–135] . However, the
mount of e.g. collagenase units used is arbitrary, since the num-
er of active protease units within the healthy/degenerated IVD
as only been reported for lysozyme to the best of our knowl-
dge [136] and also depends on the degeneration state of the
isc. quantification of ECM degrading enzymes within the NP of
egenerated discs is necessary, not only to enable appropriate
n vitro biomaterial degradation studies, but also for establish-
ng more accurate IVD degeneration models for in vivo studies.
elating the levels of e.g. matrix metalloproteinases to grading
cores for IVDs would enable more differentiated in vitro / ex vivo
pproaches targeting individual stages of DDD. For hydrolytically
egradable gels, in vitro degradation timeframes don’t necessarily
eflect in vivo conditions [137] . Intradiscal implantation is neces-
ary for accurate measurements of degradation properties for these
aterials. 
One strategy to improve biomaterial stability and mechanical
roperties is by crosslinking of the polymer [138] . A comprehen-ive review on crosslinking methods for biomaterial applications
as been published by Reddy et al ., discussing the various agents
mployed in hydrogel crosslinking [139] . In some studies glu-
araldehyde is used for crosslinking of materials [140–142] despite
ts known cytotoxic effects [143] . Ionic crosslinking of natu-
al polymers, e.g. alginate scaffolds in CaSO 4 /CaCl 2 -solutions
117 , 118 , 144–147] might present a viable alternative, however
he increased calcium-ion concentration in the disc might al-
er mechanotransduction of AF cells, cell survival of NP cells
nd lead to CEP degeneration [148–150] . Enzymatic crosslink-
ng using microbial transglutaminase has yielded promising
esults for peptide-based hydrogels but demands enzyme-removal
efore in vivo application [151–153] . For all crosslinking meth-
ds cell attachment and matrix remodelling depend on the
rosslinking-degree, and an optimum between biomaterial stiff-
ess and cytocompatibility must be achieved [154 , 155] . 
Ultimately, screening for leachable monomers of the biomate-
ial, crosslinking agent, as well as other reagents used needs to
e considered before in vivo assessment. Monitoring the degra-
ation process can be done by assessing the average molecular
eight (MW), and the distribution of MWs within the sample.
specially with slowly degrading materials, timeframes covering
everal months might be necessary to evaluate the biomaterial’s
egradation behaviour and the resulting biocompatibility in pres-
nce of degraded material. Leachable components from the mate-
ial should be extracted in polar and non-polar solvents and sub-
equently identified via e.g. HPLC-MS [156] . Cell density in the NP
as been reported at ≈4 × 10 3 cells/mm 3 ( ≈200 cells/mm 2 ) and
hould be aimed for when trying to mimic conditions found in the
P in e.g. MTT/Alamar Blue-based viability assays to study the ef-
ect of the biomaterial on NP cells in a 2D/3D environment [157] . 
NP cells express a variety of markers including BCAM, CD24, in-
egrin α6, α3, and β4, keratin 8 and 19, laminin α5, Forkhead Box
1, Paired Box 1, N-cadherin, and vimentin, which can be checked
o get a detailed response profile to the biomaterial over time
158 , 159] . The timeframe for in vitro cell culture depends on the
imeframe for biomaterial degradation obtained by previous im-
ersion experiments in PBS (see above). Notably, only few studies
urrently perform their in vitro experiments under hypoxic condi-
ions, although oxygen levels were measured at ≈2.6–13% in vivo
nd low availability of oxygen has been shown to increase ECM
roduction by bovine NP cells in culture [48 , 160] . When using a
iomaterial as a carrier for cells, growth factors, or NSAIDs fur-
her aspects such as type, concentration and release of bioactive
olecules/survival of cells have to be considered and have been
eviewed elsewhere [161–167] . 
Cell infiltration into the material can be obtained by observing
 cross-section of the biomaterial after incubation with cells for
–30 days via histology [168] . Several approaches for cell seed-
ng and assessment of cell infiltration have been published so
ar, the easiest of which is to apply cells on top of the mate-
ial in question. More complex approaches utilizing transwell se-
ups could be employed to investigate e.g. cell immune recruit-
ent. Evaluation is typically done via light microscopy, but can
e complemented by electron microscopy [169 , 170] . Histological
tains employing hematoxylin/eosin, Alcian Blue and/or Picrosir-
us Red/Masson’s Trichrome can quickly convey information about
he cell infiltration, GAGs and collagen, respectively, on synthetic
caffolds. More specific immunohistochemical methods detecting 
pecies-specific ECM molecules might be necessary to differenti-
te cell-derived matrix deposition in biomaterials obtained through
issue decellularization from the biomaterial itself for example
y utilizing species-specific antibodies. Infiltration and response
f macrophages can be investigated again via immunohistochem-
stry, or flow cytometry/ELISAs/quantitative polymerase chain re-
ction (qPCR) [171 , 172] . Macrophages of both type M1 and M2
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Fig. 6. Current methodologies for in vivo studies investigating potential biomaterials for nucleus pulposus restoration/regeneration. 
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s  are found in the IVD, and their incidence has been correlated
to IVD degenerative state [173] . However while M1 macrophages
are generally detrimental to tissues leading to increased cytokine
levels, which in the disc would trigger further degeneration, M2
macrophages are considered reparative and could be beneficial fol-
lowing initial biomaterial implantations. Macrophage response to
biomaterial application in the NP can therefore be investigated uti-
lizing these subtypes and their relative amounts. Assuming later
stages of IVD degeneration with AF and CEP tears and increased
vascularization, potential macrophage recruitment and polariza-
tion can be investigated using M0 macrophages. Crosstalk between
IVD resident cells and macrophages in degeneration presents a
further avenue in IVD degeneration model research [174] , and
should also be considered in biomaterial-mediated cell-delivery
approaches. This is particularly important to consider in relation
to the catabolic phenotype of native degenerate IVD cells which
could drive macrophages to the M1 phenotype. Analogue to the
study of Silva et al ., (progenitor) cells can be cultured within the
biomaterial with macrophages exerting indirect influence from a
transwell insert or co-culture and should be further enhanced with
co-cultures of IVD cells from degenerate human IVDs in the bio-
material [174] . ECM composition after cell-/macrophage-mediated
regeneration should ideally resemble the healthy, pre-degenerate
state, i.e. exhibiting > 600 μg/mg dry weight GAGs, and ≈20 μg/mg
dry weight collagen with > 85% being collagen type II [43] . Cell
morphology ideally should resemble the rounded NP cell [ 175 ]. 
3.6. Biocompatibility assessment in vivo 
Biocompatibility and functional in vivo studies are paramount
to assess the suitability of the biomaterial for IVD regeneration
( Fig. 6 ). The persistence of notochordal cells (NCs) within the NP
in certain animal species (e.g. rodents, porcine and some canines)
should be taken into account when choosing an animal species
for a study: NCs are thought to secrete a distinct set of soluble
stimulating factors leading to increased ECM production by NPCs
[176–179] and thereby are not representative of the human disease
environment and confound any effect of the implanted biomate-
rial alone. Thorpe et al . (2018) recommend murine and leporine
animals for initial safety studies, while larger mammals such as
sheep, goats, alpacas and (non-)chondrodystrophic dogs provide
information on the clinical efficacy of the material in question [38] .
Subcutaneous implantation could provoke an immune response
not occurring within the intended setting of the biomaterial in
the IVD, and thus to premature exclusion of an otherwise suitable
material. Implantation into the IVD mimics the intended use and
allows for determination of several disc associated parameters (e.g.
retention of disc height, fibrous encapsulation of implant or cell
infiltration, ECM production, remodelling of implant etc.). Complicating the comparison of in vivo study results are the
arious methods used to induce disc degeneration within the study
nimals, including AF puncture/incision [180–186] , nucleotomy
187–192] , discectomy [118 , 193 , 194] and enzymatic degradation
195] , next to spontaneous degeneration models [196] . Comprehen-
ive reviews of animal disc degeneration models and their limi-
ations have been compiled by Lotz et al . (2004) and Alini et al .
2008) and offer great insight into this topic [62 , 64] . In annular
uncture models and enzymatic digestion a gradual decrease in
P volume and pressure is observed, and the adaption of the disc
ells to these processes mimics the stress- and fibrotic response
bserved in human degenerated discs. Especially in enzymatically
nduced disc degeneration, the effects of the enzyme(s) and av-
nues for their inactivation need to be studied ex vivo prior to us-
ge in vivo . The differing specificity for ECM-component cleavage
f e.g. trypsin compared to hyaluronidase and their natural occur-
ence in mammals further influence their applicability in degen-
ration models as discussed by Fusellier et al . [197] . As enzyme
mount and degeneration grade have not been correlated yet in
DD, mimicking the conditions found in the NP accurately is rather
ifficult and may lead to an altered IVD degeneration progression
ompared to the naturally occurring pathophysiology. Especially for
egenerative approaches application of too high enzyme concentra-
ions may lead to a diminished observed ECM-production by res-
dent/applied cells, as there’s no way to inactivate enzymes once
njected so far. 
Nucleotomy with minimal trauma to the AF results in IVD de-
eneration and may be appropriate to use for the evaluation of NP
ugmentation strategies only after sufficient time of repair of the
njured AF. In this regard, testing NP augmentation immediately af-
er nucleotomy to induce disc degeneration would be not advisable
ue to the sudden alteration in disc physiology and biomechanics.
iscectomy as a control in vivo is only needed when examining a
hole-disc-replacement approach. 
Another problem arises due to the application of biomaterials
r cells into the NP via injection or insertion. This may damage
he AF in the process, often inducing degenerative processes itself
ater on [198–200] . Various sealing methods for the AF have been
xplored with often unsatisfactory results, i.e. incomplete sealing
f the NP and extrusion of the biomaterial into the AF [201] . Es-
ecially when applying progenitor cells into the NP, extrusion of
he cells into surrounding tissues can lead to unwanted tissue-
ormation outside the NP/AF resulting in e.g. osteophyte formation
200 , 202] . Due to its central location within the IVD, biomaterial
pplication into the NP always requires sealing and repair of the
urrounding penetrated tissue. Consequently, minimizing the dam-
ge to these tissues is a prerequisite for clinical success, and test-
ng the injectability of the material through a needle into the tis-
ue and evaluating whether the material’s properties are affected
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Ps paramount and should assume a prominent role in coming re-
earch effort s. Elliott e t al . f ound that a needle diameter < 25% of
he disc height reduces the damage occurring via annular punc-
ure to a minimum and thus should be considered when testing
he biomaterial in vivo / ex vivo [203] . Within this context, to our
nowledge the effect of the needle tip design on the AF during
njection has not been explored as a possible avenue of minimiz-
ng trauma. Whether an AF sealant after biomaterial injection is
uccessful can be investigated by testing extrusion of the mate-
ial into the injection canal under multiple degrees of freedom
ith physiological cyclic loading. Preformed materials for implan-
ation into the NP may require a larger AF defect to be made
han injectable ones. Recently, high-density collagen patches have
een explored for annulus repair with promising results, poten-
ially enabling use of preformed sponges/gels for NP augmenta-
ion [204–206] . Therefore, further research is necessary as espe-
ially moderate degeneration might profit from the combined ap-
roach. Incorporation of radiopaque substances into the biomate-
ial is important for controlled application and tracing in the pa-
ient, but the choice of substance (iodine-/metal-based [207 , 208] )
nd their interaction with NP tissue and cells has not been studied
xtensively so far, and needs to be elucidated in coming research
fforts. 
An important aspect for in vivo studies is the observed time-
rame. Periods of two to sixteen weeks postoperatively have been
onsidered in experiments thus far. Comparing the results of these
tudies consequently is very difficult. Acute inflammation shows
ymptoms rapidly within the first hours to days after implanta-
ion, with chronic inflammation potentially setting in afterwards
209] . To accurately assess the biocompatibility of an implanted
aterial, considering a timeframe that covers the material’s in vivo
egradation is essential to observe potential immune reactions
o degradation products. Similarly, implant retention within the
VD, stability of disc height, and biomaterial remodelling in combi-
ation with ECM deposition within the NP over these time periods
ontribute to a better understanding of the material efficacy. De-
ermining the timeframe needed however is difficult and depends
n the material in question and is further impeded by the lack of
onsensus for in vitro degradation methodology. 
In conjunction with in vivo studies, several grading param-
ters have been established to facilitate comparison between
egenerative states of IVDs, and their (dis)advantages have beenable 6 
arameters to evaluate for potential NP restoration biomaterials, and corresponding asses
Characterization parameter Technique 
Material properties Viscosity, stiffness Rheometry 
Stress/relaxation behaviour, 
aggregate modulus 
Compression testing 
Poisson ratio Compression testing 
Pore size SEM 
Porosity SEM 
Crosslinking degree Crosslinker-dependant 
Crystallinity Differential scanning calorimetr
Swelling degree Gravimetric measurement of 
weight increase iscussed in detail by Kettler et al . [210] . They recommend the use
f seven grading schemes related to the lumbar spine. Magnetic
esonance imaging (MRI) presents a powerful non-invasive tech-
ique for evaluating several degeneration- and therapy-associated
arameters. Not only is it possible to assess the disc height but
dditionally, the Pfirrmann scale allows for determination of the
egeneration state taking into account T2 weighted images that
onvey information about the hydration level of the NP [211] . Of-
en these two parameters are also combined into an “MRI-index”
y multiplying the NP pixel area or volume with the signal in-
ensity [183 , 212] . An increase in hydration initially however could
imply be a result of injection of the material and thus demon-
trating maintenance of increased signal intensity over time is
ssential. 
Assessing the degeneration state of the tissue histologically us-
ng macroscopic Thompson’s or microscopic Boos’ scores provides
nformation on the pre- and post-intervention state of the tissue.
hese are acquired with ≥2 trained investigators rating histologi-
al sections from the sagittal plane made from spinal motion seg-
ents [175 , 213] . Importantly, clinically relevant outcome param-
ters (e.g. pain) are rarely evaluated in the experimental studies
onducted thus far [38 , 214] , while guidelines within this context
re largely lacking and would have the ability of linking the exper-
mental work to the clinical situation. 
. Conclusion 
Functional NP restoration and regeneration using biomaterials
resents a promising approach towards IVD regeneration. Evaluat-
ng the biomaterials within the context of clinical applicability and
fficacy however presents a challenge itself. Data on the molecular,
ell and tissue level must be gathered and supplemented by exper-
ments determining the material’s mechanical properties, needed
or restoration of the disc’s or motion segment’s biomechanical
ehaviour. Further regeneration to a healthier state of the NP is
lso possible with a material which supports matrix deposition and
mbedded bioactive components ( Fig. 1 ). As more studies are pub-
ished, working towards a more unified set of characterization ex-
eriments will allow for more streamlined identification of viable
P restoration and regeneration biomaterials as well as strategies
or testing them in a clinical setting. Recommended assessment
ethods and further resources can be found in Table 6 . sment methods and further reading. 
Approach 
Oscillation rate 0.1–100 rad/s, ≈10% strain, 37 °C 
Strain sweep from 0.1–100% strain at ≈30 rad/s, 37 °C 
Temperature sweep covering 20 °C - 37 °C at ≈10% strain, ≈30 rad/s 
(Sample drying prevented by e.g. PBS + FBS 1 application around sample) 
Confined compression at 37 °C in PBS + FBS, 10 7 cycles/until material failure in ex 
vivo setup 
Unconfined compression or digital image correlation (refer to [93] ) at 37 °C 
Lyophilization as sample preparation technique after freezing in liquid N 2 to 
minimize physical influence on poresize measured. Alternatively: environmental 
SEM. 
Sectioning of scaffold. ImageJ with jPOR macro for analysis. Refer to Loh et al . [81] 
E.g. commercial 2,4,6-Trinitrobenzenesulfonic acid (TNBS)/ninhydrin kit to 
measure amount of free amine residues 
y Performed on dried samples, temperature ramp of 10 °C/min under N 2 flow 
Immersion in PBS + FBS over time, weight measurements at predetermined 
timepoints. Swel ling degr ee = m wet −m dry m dry ∗ 100% 
( continued on next page ) 
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Table 6 ( continued ) 
Characterization parameter Technique Approach 
Sterilization Efficacy Quantify microbial load Refer to FDA guidelines [66 , 67] 
Effect on material properties See above See above 
Biological response 2 (Bio)degradation No current accepted standard Immerse in PBS ± enzymes/implant intradiscally for ≥30 days, monitor release of 
degradation products by e.g. HPLC-MS, NMR, BCA assay or similar, depending 
on biomaterial components 
Additional measurement of degradation in acidic milieu 
Cell compatibility 3 Viability 3-(4,5-dimethylthiazol-2-yl) −2,5-diphenyltetrazolium bromide (MTT) assay 
Function Gene expression, matrix deposition (1,9-Dimethyl-Methylene Blue (DMMB), 
Hydroxyproline assay (HYP)) 
Morphology Microscopy 
Infiltration Microscopy of haematoxylin & eosin staining 
Histological evaluation Microscopy of alcian blue- and picrosirius red/Masson’s trichrome-stained sections 
to visualize GAGs and collagen, respectively 
Tissue compatibility Fibrous encapsulation Microscopy 
Cell infiltration (Fluorescence) Microscopy via haematoxylin&eosin/4 ′ ,6-diamidino-2-phenylindole 
(DAPI) 
Non-neurogenic effect Culture material in presence of neural cells (refer to [215] ) 
Remodelling Microscopy on immunohistochemistry, matrix deposition (DMMB, HYP assay) 
Blood compatibility Complement activation assay 4 Commercial ELISA 
Non-angiogenic effect Culture material in presence of human umbilical vein endothelial cells (refer to 
[215] ) 
Immunological compatibility α-Gal-epitope quantification 
(where applicable) 
ELISA 
Macrophage polarization FACS/qPCR/ELISA/immunostaining 
Immune cell infiltration Microscopy using cell tracking dye 
In Vivo study design Intradiscal implantation of 
material 
Rabbit or larger mammal 
Degeneration model Annular puncture/enzymatic digestion/spontaneous(/nucleotomy) 
Timeframe Study timeframe > in vitro degradation timeframe where possible 
Morphological evaluation Thompson score (macroscopy), Boos scores (histology), Pfirrmann score (MRI), 
MRI index = NP area or v olume ∗ T 2 pixel signal intensity 
In Vivo toxicity Full blood count analysis Full blood count via FACS/hemocytometer 
Quantify endotoxin & pyrogen 
levels 
Commercially available Limulus Amebocyte Lysate reagent test or alternatives 
Key organs’ appearance Organ morphology investigated by pathologist 
Liver and kidney function testing Investigate Kidney function via serum creatinine [216] ELISA 
Investigate liver function via serum concentrations of alanine 
aminotransferase/glutamate dehydrogenase ELISA and/or mtDNA/nuclear DNA 
fragments [217] via DNA isolation & gel electrophoresis 
Injectability Injection into cadaveric motion 
segment 
Cell viability within material 
during/after injection 
MTT assay, Calcein-AM/Propidium iodide staining 
Injection pressure Measure manual pressure applied to syringe 
Gauge size necessary for 
application 
Must be as small as possible, < 25% of disc height 
Incorporation of radiopaque 
substances [218] 
μCT/MRI scan 
Biomechanics 5 Range of motion Measure maximum angle Measure maximum angle from photo/video/software in ex vivo spinal setup 
Stiffness Determine neutral and elastic zone stiffness (refer to [219 , 220] ) 
Mechanical restoration Disc height index [221] Measure disc & vertebral body height from photo/video. 
Disc Height Index = 2( DH 1+ DH 2+ DH 3 ) 
( LB 1+ LB 2+ LB 3 )+( U B 1+ U B 2+ U B 3 ) DH: disc height, LB: lower 
vertebral body height, UB: upper vertebral body height 
Stiffness Determine functional spine unit (FSU) stiffness under uniaxial loading, and under 
dynamic and diurnal loading 
Biomaterial failure Fatigue testing Same conditions as confined compression testing, loading cycles until failure 
Material extrusion Human FSU with implanted/injected stained material bent within the human 
ROM and checked visually for expulsion of material. Bending outside of human 
ROM can report on critical angle/load for expulsion to happen. Material can also 
be radiolabeled and then checked in CT during the above-mentioned tests 
1 In this context refers to PBS + FBS with a final protein concentration of 20 g/l in the combined solution with osmolarity matching that of the (diseased) NP. 
2 Refer to ISO10993, ASTM guideline F2150–13, FDA document 1637. 
3 Optimally in hypoxic conditions (O 2 ≤13%). 
4 See also Peakman et al. [222] . 
5 Refer to Newell et al. [89] . 
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